Currently, out of the existing stock ratings of Tessa Romero - 27 which are a Buy (61.36%), 14 which are a Hold (31.82%), 3 which are a Sell (6.82%)

Tessa Romero

Work Performance Price Targets & Ratings Chart

Analyst Tessa Romero works at JPMORGAN and is covering the Healthcare sector with 75 price targets and ratings displayed on 11 stocks.

Tessa Romero's average stock forecast success ratio is 31.06% with an average time for price targets to be met of 29.91 days.

Most recent stock forecast was given on BHVN, Biohaven Pharmaceutical Holding Company Ltd at 20-Nov-2023.

Wall Street Analyst Tessa Romero

Analyst best performing recommendations are on GBT (GLOBAL BLOOD THERAPEUTICS).
The best stock recommendation documented was for BHVN (BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD) at 5/17/2023. The price target of $21 was fulfilled within 16 days with a profit of $6.88 (48.73%) receiving and performance score of 30.45.

Average potential price target upside

EWTX GBT Global Blood Therapeutics ORTX Orchard Therapeutics plc ATRA Atara Biotherapeutics RIGL Rigel Pharmaceuticals SRRK Scholar Rock YMAB YmAbs Therapeutics CYTK Cytokinetics XENE Xenon Pharmaceuticals ACAD ACADIA Pharmaceuticals BHVN Biohaven Pharmaceutical Holding Company Ltd

Analyst name


Current price target

Potential distance

Previous price target


Price targets met ratio

Average potential upside

Average time for PT to be met

Performance score


4 months 30 days ago

0/2 (0%)

$13.43 (74.24%)



$-0.73 (-12.74%)


1 years 3 months 4 days ago

2/4 (50%)

$-1.91 (-19.46%)




$24.27 (423.56%)


1 years 6 months 17 days ago

0/2 (0%)

$14.91 (164.45%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Tessa Romero is most bullish on?

Potential upside of $9.88 has been obtained for ACAD (ACADIA PHARMACEUTICALS)

Which stock is Tessa Romero is most reserved on?

Potential downside of -$0 has been obtained for EWTX

What Year was the first public recommendation made by Tessa Romero?

On 2017

To continue looking at which analysts cover the stock please register to the basic or advanced membership

How to use the chart